Drug file · From the Watchtower
Durvalumab: the briefings and the record
Every Prognyx briefing on durvalumab, newest first, and the dated events drawn from the sources those briefings cite. Rebuilt with each new briefing.
- Also known as
- MEDI4736, Imfinzi
- Target, as briefed
- PD-L1 checkpoint inhibitor + Nectin-4 antibody-drug conjugate; PD-L1 checkpoint inhibitor + DLL3 x CD3 T-cell engager
- Companies named
- AstraZeneca, Amgen
- Prognyx coverage
- 3 briefings, 8 September 2026 to 14 November 2026
Prognyx briefings on durvalumab
- muscle-invasive bladder cancer (neoadjuvant/adjuvant perioperative)FDA approves AstraZeneca's Imfinzi plus enfortumab vedotin for perioperative MIBC
- first-line extensive-stage small cell lung cancer (maintenance)Amgen's Imdelltra plus Imfinzi cuts death risk 58% in first-line ES-SCLC
Phase III DeLLphi-305 data, presented at ESMO and published in NEJM, cut the risk of death by 58% for the tarlatamab plus durvalumab first-line maintenance combination versus durvalumab alone in extensive-stage small cell lung cancer.
- first-line extensive-stage small cell lung cancerAstraZeneca reports durvalumab-tarlatamab maintenance improves survival in first-line ES-SCLC
The company's 8 September press release reports statistically significant overall and progression-free survival gains from adding tarlatamab to durvalumab first-line maintenance, after durvalumab plus platinum-etoposide induction, in NCT07005128; no hazard ratios, medians or p-values were released.
Sourced timeline
Readouts, regulatory actions, filings, trial starts and deals that the Prognyx engine extracted from the documents cited in these briefings, newest first. Each links to its source and to the briefing that cited it. Press coverage is left out, and so is any event dated on its own briefing's day: the briefing above is the record for that day. A month without a day is a date the source gave only to the month.
- Regulatory actionFDA approves perioperative durvalumab + enfortumab vedotin in MIBCFDA OCE · cited in FDA approves AstraZeneca's Imfinzi plus enfortumab vedotin for…
- Regulatory actionImfinzi POTOMAC-based NMIBC approval in JapanSEC 6-K · cited in FDA approves AstraZeneca's Imfinzi plus enfortumab vedotin for…
- Regulatory actionFDA accelerated approval in previously treated advanced bladder cancerAstraZeneca newsroom · cited in FDA approves AstraZeneca's Imfinzi plus enfortumab vedotin for…
- DesignationFDA Breakthrough Therapy designation in PD-L1+ urothelial bladder cancerAstraZeneca newsroom · cited in FDA approves AstraZeneca's Imfinzi plus enfortumab vedotin for…
Registered trials on file
ClinicalTrials.gov records that the cited sources tie to durvalumab, each opening on the registry.
The Watchtower, by email
The next move on durvalumab, the day it happens.
The next readout, FDA/EMA action or deal on durvalumab reaches you by email the day we publish it. One email per briefing, nothing else.
Double opt-in. Never sold, no open tracking. Privacy.
Get a free sample competitive brief on one of your assets, sourced, sharp, no strings.
Request a sample brief → Or read how Prognyx runs continuous oncology competitive intelligence.
Prognyx briefings are built from public information and reflect Prognyx's analysis. They are not investment advice and do not promote any product or off-label use. Event titles are written by the Prognyx engine from the linked source; the source is the record.